A Randomized Phase 2 Study of Nivolumab Monotherapy Versus Nivolumab Combined With Ipilimumab in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor (GIST)
Latest Information Update: 22 Aug 2022
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 15 Aug 2022 Status changed from active, no longer recruiting to completed.
- 31 Jan 2022 Planned End Date changed from 1 Jan 2022 to 1 Sep 2023.
- 31 Jan 2022 Planned primary completion date changed from 1 Sep 2021 to 30 Sep 2022.